Premium
Analysis of CC chemokine receptor 5 and 2 polymorphisms and renal transplant survival
Author(s) -
Yigit Bulent,
Bozkurt Nilufer,
Berber Ibrahim,
Titiz Izzet,
İsbir Turgay
Publication year - 2006
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.1322
Subject(s) - chemokine , transplantation , immunology , chemokine receptor , medicine , allele , renal transplant , population , incidence (geometry) , gastroenterology , immune system , biology , gene , genetics , environmental health , physics , optics
Chronic rejection is an immune process leading to graft failure. By regulating the trafficking of leukocytes, chemokines and chemokine receptors are thought to be one of the reasons causing acute renal rejection (ARE), which increases the possibility of chronic rejection and organ destruction. This study was designed to investigate, in the Turkish population, an association of chemokine receptor genetic variants, CCR2V641, CCR5‐59029–A/G, CCR5‐Δ32 and acute renal rejection after renal transplant surgery. We carried out our study in 85 Turkish renal transplant patients (45 men, 40 women; mean age 39 ± 2 years) by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) techniques. We found no significant difference in the incidence of rejection among patients possessing or lacking CCR5‐Δ32. For the groups with and without acute renal rejection, we found a significant difference between the groups in A and G allele distribution in both CCR2V641and CCR559029 gene variants ( p = 0.003 and p = 0.003, respectively). According to our findings, the risk of acute rejection in renal transplantation may be associated with genetic variation in the chemokine receptor genes CCR5‐59029 and CCR2V641 in Turkey, and studies on these gene polymorphisms could be an ideal target for future interventions intended to prevent renal transplant loss. Copyright © 2006 John Wiley & Sons, Ltd.